¿Se debe tener en cuenta el género para revascularizar el tronco?

Should Sex Be Taken into Account with Left Main Coronary Artery Revascularization?

The EXCEL trial did not find the sex of patients with left main coronary artery disease to be an independent predictor of adverse events after revascularization. However, women who underwent angioplasty had a trend towards worse outcomes, a finding that might be related to comorbidities and somewhat increased chances of peri-procedural complications. In its formal<a href="https://solaci.org/en/2018/07/10/should-sex-be-taken-into-account-with-left-main-coronary-artery-revascularization/" title="Read more" >...</a>

CTO Revascularization Improves Quality of Life

Courtesy of Dr. Carlos Fava. The presence of CTO hovers around 15, 20% in coronary angiographies of patients with chronic stable angina, but only 5% receive percutaneous coronary intervention (PCI). One of the obstacles to percutaneous revascularization is the lack of relevant studies justifying it, though we do have different comparative studies that improve symptoms, ventricular<a href="https://solaci.org/en/2018/06/08/cto-revascularization-improves-quality-of-life/" title="Read more" >...</a>

EuroPCR 2018 | Ultimaster Registry: Difference in Strut Thickness

This work compared the safety and efficacy of angioplasty with thin-strut (80 µm) sirolimus-eluting stents with a cobalt chromium structure (Ultimaster) vs. thick-strut (120 µm) biolimus-eluting stents with a cobalt chromium structure (Nobori). This study compared two prospective multicenter single-arm registries: e-Ultimaster and NOBORI 2. The Ultimaster Registry included over 37,000 patients in 4 continents, while the NOBORI 2 Registry included<a href="https://solaci.org/en/2018/05/31/europcr-2018-ultimaster-registry-difference-in-strut-thickness/" title="Read more" >...</a>

DES de 2° vs 3° generación en bifurcaciones: nada nuevo bajo el sol

EuroPCR 2018 | 2nd and 3rd-Generation DES for Bifurcation Lesions: Nothing New Under the Sun

This study aimed to assess the outcome of Culotte stenting with newer-generation drug-eluting stents (DES) in Medina 1, 1, 1 bifurcation lesions. The 2nd-generation device used was permanent-polymer everolimus-eluting stent Xience, a device for which there is comparatively plenty of evidence available. Alternatively, the 3rd-generation stent used was thin-strut abluminal bioresorbable-polymer everolimus-eluting stent SYNERGY. Patients with<a href="https://solaci.org/en/2018/05/31/europcr-2018-2nd-and-3rd-generation-des-for-bifurcation-lesions-nothing-new-under-the-sun/" title="Read more" >...</a>

OxAMI-PICSO: oclusión del seno coronario: mejorar la función microvascular y reducir el tamaño del infarto

EuroPCR 2018 | OxAMI-PICSO: Coronary Sinus Occlusion, Improving Microvascular Function and Reducing Infarct Size

The index of microcirculatory resistance might guide therapy and controlled intermittent coronary sinus occlusions, improve microvascular function, and reduce infarct size. This study included patients with prior ST-segment elevation myocardial infarction treated with primary angioplasty. Researchers measured the index of microcirculatory resistance before stenting and intermittent coronary sinus occlusion was used if the result was<a href="https://solaci.org/en/2018/05/31/europcr-2018-oxami-picso-coronary-sinus-occlusion-improving-microvascular-function-and-reducing-infarct-size/" title="Read more" >...</a>

BIO-RESORT: polímeros vs polímeros bioabsorbibles ¿Llegamos a una meseta con los DES?

EuroPCR 2018 | BIO-RESORT: Polymer vs. Bioresorbable Polymer; Have We Reached a Plateau with DES?

This study randomized 3514 patients to a thin-strut biodegradable polymer everolimus-eluting stent (SYNERGY) vs. a sirolimus-eluting stent (ORSIRO) vs. a durable polymer zotarolimus-eluting stent (RESOLUTE INTEGRITY). The combined endpoint, the rate of target vessel failure, was similar for all three devices (8.3% for the zotarolimos-eluting stent, 6.8% for the everolimus-eluting stent, and 6.6% for the sirolimus-eluting<a href="https://solaci.org/en/2018/05/29/europcr-2018-bio-resort-polymer-vs-bioresorbable-polymer-have-we-reached-a-plateau-with-des/" title="Read more" >...</a>

Debemos hacer la mejor revasculirazión coronaria previo al TAVI

Do the Best Coronary Revascularization Prior TAVR

The presence of coronary artery disease (CAD) in patients with aortic stenosis is high, reaching 50% to70% of cases. This poses a great challenge as to what strategy to use and the things we can do. Even though it has been shown complete revascularization is beneficial, it is often difficult to achieve. Instead, reasonable incomplete<a href="https://solaci.org/en/2018/04/18/do-the-best-coronary-revascularization-prior-tavr/" title="Read more" >...</a>

TCT 2017 | SENIOR: DES con polímero reabsorbible y tiempo de doble antiagregación corto en pacientes añosos

TCT 2017 | SENIOR: DES with a Bioresorbable Polymer and Short Dual Antiplatelet Therapy in Elderly Patients

 Courtesy of the SBHCI. This study sought to assess the safety and efficacy of an everolimus-eluting stent with a biodegradable polymer (SYNERGY II) vs. a conventional stent (REBEL) in patients >75 years old with short duration of dual antiplatelet therapy. Before randomization, investigators recorded the planned duration of dual antiplatelet therapy (1 month for stable patients and 6 months<a href="https://solaci.org/en/2017/11/03/tct-2017-senior-des-with-a-bioresorbable-polymer-and-short-dual-antiplatelet-therapy-in-elderly-patients/" title="Read more" >...</a>

Introducing the number one enemy of PCI: diabetes

About 25% of patients with multivessel disease undergoing myocardial revascularization surgery or PCI have diabetes.   In this subgroup, the benefit of surgery in terms of mortality has long been shown: in the BARI study (Bypass Angioplasty Revascularization Investigation) patients undergoing PCI had close to double the mortality rate at 5 years compared to those<a href="https://solaci.org/en/2017/09/22/introducing-the-number-one-enemy-of-pci-diabetes/" title="Read more" >...</a>

Sorpresivo hallazgo en diabetes y permeabilidad de los bypass

Striking Finding on Diabetes and Bypass Graft Patency

The higher rate of restenosis in the diabetic population is historic and has been reproduced in all studies and with all kinds of stents, but it was only after the FREEDOM trial when we found out about the higher infarction rate with PCI compared to surgery. This is why 50% of patients undergoing CABG are diabetic. Apart from the above<a href="https://solaci.org/en/2017/09/01/striking-finding-on-diabetes-and-bypass-graft-patency/" title="Read more" >...</a>